Outcomes toolbox for head and neck cancer research

Head and Neck

Volumn 37, Issue 3, 2015, Pages 425-439

  Ringash, Jolie ^a   Bernstein, Lori J ^b   Cella, David ^c   Logemann, Jerilynn ^c   Movsas, Benjamin ^d   Murphy, Barbara ^e   Trotti, Andrea ^f   Wells, Nancy ^e   Yueh, Bevan ^g   Ridge, John ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

Clinical trials; Head and neck neoplasms; Outcomes; Quality of life; Questionnaires

Indexed keywords

ACUTE TOXICITY; ANXIETY; BODY IMAGE; CANCER PAIN; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); COGNITION; DENTAL HEALTH; DEPRESSION; DISABILITY; DRUG ERUPTION; FATIGUE; FEASIBILITY STUDY; HEAD AND NECK CANCER; HUMAN; HYPOSALIVATION; MEDICAL SOCIETY; MUCOSA INFLAMMATION; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DERMATITIS; REVIEW; SHOULDER DISEASE; SKIN MANIFESTATION; SLEEP; SOCIAL ISOLATION; SPEECH DISORDER; SWALLOWING; TRISMUS; TUMOR VOLUME; VALIDITY; XEROSTOMIA; FEMALE; HEAD AND NECK NEOPLASMS; MALE; MEDICAL RESEARCH; MORTALITY; PRACTICE GUIDELINE; RISK ASSESSMENT; SURVIVOR;

BIOMEDICAL RESEARCH; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; PATIENT OUTCOME ASSESSMENT; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVORS;

EID: 84923077211     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23561     Document Type: Review

References (108)

1. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
2. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25:5121-5127.
3. NCI Common Terminology Criteria for Adverse Events (CTCAE). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. 2009. Accessed June 25, 2013.
4. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007;29:923-931.
5. Cleeland CS. The M.D. Anderson Symptom Inventory User Guide. 2010. Available at: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/MDASI_userguide.pdf. Accessed June 25, 2013.
6. Murphy BA, Dietrich MS, Wells N, et al. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck 2010;32:26-37.
7. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
8. Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 2005;113:37-44.
9. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17:197-210.
10. Cleeland CS. Assessment of pain in cancer: measurement issues. New York, NY: Raven Press; 1990. 16.
11. Lee JY, Chen HI, Urban C, et al. Development of and psychometric testing for the Brief Pain Inventory-Facial in patients with facial pain syndromes. J Neurosurg 2010;113:516-523.
12. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med 2009;24:733-738.
13. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-299.
14. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30: 191-197.
15. Bahmer FA, Smolle J. Morphometry in clinical dermatology. Acta Derm Venereol 1992;72:52-55.
16. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17:291-296.
17. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-149.
18. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341-1346.
19. Momm F, Bartelt S, Haigis K, Grosse-Sender A, Witucki G. Spectrophotometric skin measurements correlate with EORTC/RTOG-common toxicity criteria. Strahlenther Onkol 2005;181:392-395.
20. Multinational Association of Supportive Care in Cancer. MASCC EGFR inhibitor skin toxicity tool (MESTT). 2013. Available at: http://www.mascc.org/MESTT. Accessed June 25, 2013.
21. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010;18:509-522.
22. Epstein JB, Beaumont JL, Gwede CK, et al. Longitudinal evaluation of the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer, a patient-reported outcomes questionnaire. Cancer 2007;109:1914-1922.
23. Mueller C, Compher C, Ellen DM; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition screening, assessment, and intervention in adults. JPEN J Parenter Enteral Nutr 2011;35:16-24.
24. Kruizenga HM, Van Tulder MW, Seidell JC, Thijs A, Ader HJ, Van Bokhorst-de van der Schueren MA. Effectiveness and cost-effectiveness of early screening and treatment of malnourished patients. Am J Clin Nutr 2005;82:1082-1089.
25. Wolinsky FD, Coe RM, McIntosh WA, et al. Progress in the development of a nutritional risk index. J Nutr 1990;120 Suppl 11:1549-1553.
26. Logemann JA, Pauloski BR, Rademaker AW. Relationship between patient perception and objective measures of swallow function in treated HNC patients. Presented at the 19th Annual Dysphagia Research Society Meeting, San Antonio, TX. March 3, 2011.
27. Logemann JA. Role of the modified barium swallow in management of patients with dysphagia. Otolaryngol Head Neck Surg 1997;116: 335-338.
28. McHorney CA, Robbins J, Lomax K, et al. The SWAL-QOL and SWALCARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia 2002;17:97-114.
29. Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001;127:870-876.
30. List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 1996;77:2294-2301.
31. Jacobson BH, Johnson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol 1997;6: 66-70.
32. Mossman KL. Quantitative radiation dose-response relationships for normal tissues in man. II. Response of the salivary glands during radiotherapy. Radiat Res 1983;95:392-398.
33. Murphy BA. A critical component of supportive care. J Support Oncol 2007;5:228-229.
34. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 66:445-453.
35. Al-Nawas B, Al-Nawas K, Kunkel M, Grötz KA. Quantifying radioxerostomia: salivary flow rate, examiner's score, and quality of life questionnaire. Strahlenther Onkol 2006;182:336-341.
36. Pai S, Ghezzi EM, Ship JA. Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:311-316.
37. Eisbruch A, Rhodus N, Rosenthal D, et al. How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 2003;13: 226-234.
38. Tsujii H. Quantitative dose-response analysis of salivary function following radiotherapy using sequential RI-sialography. Int J Radiat Oncol Biol Phys 1985;11:1603-1612.
39. Navazesh M, Kumst SK; University of Southern California School of Dentistry. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 2008;139 Suppl:35S-40S.
40. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 1987;115: 581-584.
41. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.
42. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983;41:283-288.
43. Bachmann G, Rössler R, Klett R, Rau WS, Bauer R. The role of magnetic resonance imaging and scintigraphy in the diagnosis of pathologic changes of the mandible after radiation therapy. Int J Oral Maxillofac Surg 1996;25:189-195.
44. Radiation Therapy Oncology Group. RTOG 1016 protocol information. Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. Available at: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study51016.2012. Accessed June 25, 2013.
45. Scott B, Butterworth C, Lowe D, Rogers SN. Factors associated with restricted mouth opening and its relationship to health-related quality of life in patients attending a maxillofacial oncology clinic. Oral Oncol 2008;44:430-438.
46. Duke RL, Campbell BH, Indresano AT, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope 2005; 115:678-683.
47. Kuntz AL, Weymuller EA Jr. Impact of neck dissection on quality of life. Laryngoscope 1999;109:1334-1338.
48. Goldstein D. Assessment of the Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire for use in patients following neck dissection for head and neck cancer. 2010. Available at: https://tspace.library.utoronto.ca/bitstream/1807/25599/3/Goldstein_David_P_201011_MSc_thesis.pdf. Accessed June 25, 2013.
49. Constant CR, Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res 1987;214:160-164.
50. Chepeha DB, Taylor RJ, Chepeha JC, et al. Functional assessment using Constant's Shoulder Scale after modified radical and selective neck dissection. Head Neck 2002;24:432-436.
51. van Den Ende CH, Rozing PM, Dijkmans BA, Verhoef JA, Voogt-van der Harst EM, Hazes JM. Assessment of shoulder function in rheumatoid arthritis. J Rheumatol 1996;23:2043-2048.
52. Taylor RJ, Chepeha JC, Teknos TN, et al. Development and validation of the neck dissection impairment index: a quality of life measure. Arch Otolaryngol Head Neck Surg 2002;128:44-49.
53. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med 1996;29:602-608.
54. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther 2001;14:128-146.
55. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-538.
56. PROMIS. Dynamic tools to measure health outcomes from the patient perspective. 2004. Available at: http://www.nihpromis.org. Accessed June 25, 2013.
57. Riley WT, Rothrock N, Bruce B, et al. Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banks. Qual Life Res 2010;19:1311-1321.
58. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010;63:1179-1194.
59. Rothrock NE, Hays RD, Spritzer K, Yount SE, Riley W, Cella D. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2010;63:1195-1204.
60. Smith E, Lai JS, Cella D. Building a measure of fatigue: the functional assessment of Chronic Illness Therapy Fatigue Scale. PM R 2010;2:359-363.
61. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196.
62. Barsevick AM, Cleeland CS, Manning DC, et al. ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage 2010;39:1086-1099.
63. Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer 2001;37:189-197.
64. Lundgren JD, Anderson DA, Thompson JK. Fear of negative appearance evaluation: development and evaluation of a new construct for risk factor work in the field of eating disorders. Eat Behav 2004;5:75-84.
65. Slade PD, Dewey ME, Newton T, Brodie D, Kiemle G. Development and preliminary validation of The Body Satisfaction Scale (BSS). Psychol Health 1990;4:213-220.
66. Fingeret MC, Vidrine DJ, Reece GP, Gillenwater AM, Gritz ER. Multidimensional analysis of body image concerns among newly diagnosed patients with oral cavity cancer. Head Neck 2010;32:301-309.
67. Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007;117:399-405.
68. Neuro-QOL. Quality of life in neurological disorders. 2013. Available at: http://www.NeuroQoL.org. Accessed June 24, 2013.
69. Cella D, Nowinski C, Peterman A, et al. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil 2011;92(10 Suppl): S28-S36.
70. Hong JH, Omur-Ozbek P, Stanek BT, et al. Taste and odor abnormalities in cancer patients. J Support Oncol 2009;7:58-65.
71. Cooperstein E, Gilbert J, Epstein JB, et al. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck 2012;34:797-804.
72. Bartoshuk LM. Chemosensory alterations and cancer therapies. NCI Monogr 1990;9:179-184.
73. Wrobel BB, Leopold DA. Clinical assessment of patients with smell and taste disorders. Otolaryngol Clin North Am 2004;37:1127-1142.
74. Goldberg AN, Shea JA, Deems DA, Doty RL. A ChemoSensory questionnaire for patients treated for cancer of the head and neck. Laryngoscope 2005;115:2077-2086.
75. Wickham RS, Rehwaldt M, Kefer C, et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999;26:697-706.
76. Rehwaldt M, Wickham R, Purl S, et al. Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum 2009;36:E47-E56.
77. Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012; 30:1080-1086.
78. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an indepth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 2009;3:223-232.
79. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011;12:703-708.
80. Gan HK, Bernstein LJ, Brown J, et al. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;81:126-134.
81. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008;8: 887-899.
82. Brandt J. The Hopkins verbal learning test: development of a new memory test with six equivalent forms. Revised. Clin Neuropsychol 1991;5: 125-142.
83. Reitan RM, Wolfson D. Category test and trail making test as measures of frontal lobe functions. Clin Neuropsychol 1995;9:50-56.
84. Weschler D. Wescler Adult Intelligence Scale-fourth edition WAIS-IV. San Antonio, TX: Psych Corp: 2008.
85. Klove H. Clinical neuropsychology. Med Clin North Am 1963;47:1647-1658.
86. Wagner LI, Sweet J, Jin-shei Lai ZB, Cella D. Measuring patient selfreported cognitive function. Development of the functional assessment of cancer therapy - congnitive function instrumet. J Support Oncol 2009;7: W32-W39.
87. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 2003;56:52-60.
88. Ringash J, Bezjak A. A structured review of quality of life instruments for head and neck cancer patients. Head Neck 2001;23:201-213.
89. Ojo B, Genden EM, Teng MS, Milbury K, Misiukiewicz KJ, Badr H. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol 2012;48:923-937.
90. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
91. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:1008-1019.
92. Weymuller EA, Yueh B, Deleyiannis FW, Kuntz AL, Alsarraf R, Coltrera MD. Quality of life in patients with head and neck cancer: lessons learned from 549 prospectively evaluated patients. Arch Otolaryngol Head Neck Surg 2000;126:329-335; discussion 335-336.
93. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
94. Guyatt GH, Feeny D, Patrick D. Proceedings of the International Conference on the Measurement of Quality of Life as an outcome in clinical trials: Postcript. Control Clin Trials 1991;12:266S-269S.
95. Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-287.
96. Ringash J, Bezjak A, O'Sullivan B, Redelmeier DA. Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients. Qual Life Res 2004;13:725-733.
97. Rogers SN, Lowe D, Yueh B, Weymuller EA Jr. The physical function and social-emotional function subscales of the University of Washington Quality of Life Questionnaire. Arch Otolaryngol Head Neck Surg 2010; 136:352-357.
98. Rogers SN, O'Donnell JP, Williams-Hewitt S, Chistensen JC, Lowe D. Health-related quality of life measured by the UW-QoL - reference values from a general dental practice. Oral Oncol 2006;42:281-287.
99. El-Deiry MW, Futran ND, McDowell JA, Weymuller EA Jr, Yueh B. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg 2009;135:380-384.
100. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603.
101. von Neumann J, Morgenstern O. Theory of games and economic behavior. Princeton, NJ: Princeton University Press; 1953.
102. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972;7:118-133.
103. van der Meij EH, Bezemer PD, van der Waal I. Cost-effectiveness of screening for the possible development of cancer in patients with oral lichen planus. Community Dent Oral Epidemiol 2002;30:342-351.
104. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics 1989;45:781-795.
105. Rabin R, de Charro F. EQ-5D: a measure of health status from the Euro-Qol Group. Ann Med 2001;33:337-343.
106. Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007;25:365-384.
107. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70.
108. Nordgren M, Jannert M, Boysen M, et al. Health-related quality of life in patients with pharyngeal carcinoma: a five-year follow-up. Head Neck 2006;28:339-349.